Navigation Links
UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
Date:4/3/2012

al information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of April 4, 2012 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... former senior vice president and corporate controller, has been ... effective immediately, replacing Peggy Mulligan, former chief financial officer, ... other interests.  The Company has initiated a search to ...
... (Nasdaq: STXS ) announced today that the Company ... which includes a $30 million revolving facility that matures on ... matures on December 31, 2013.  The new facility was led ... that was scheduled to mature in March 2011. ...
Cached Medicine Technology:Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO 2Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO 3Stereotaxis Completes $40 Million Credit Facility 2Stereotaxis Completes $40 Million Credit Facility 3
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014U.S. military personnel ... "blast plus impact" concussive traumatic brain injury (TBI) ... were evacuated for other medical reasons. Differences in ... and depression 6-12 months after injury are reported ... , a peer-reviewed journal from Mary Ann Liebert, ...
(Date:4/17/2014)... as 10 million older Americans suffer from depression, often ... However, new research a project that followed the ... years found that Internet use among the elderly ... 30 percent. , "That,s a very strong effect," said ... information studies and media who led the project. "And ...
(Date:4/17/2014)... 2014-- Colic affects about one in five infants in ... visits during the first several months after birth. Research ... showing promise; however, the April 1, 2014 issue of ... reported on a study, "Probiotics and Infant Colic," concluding ... for infant colic did not reduce crying ...
(Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
(Date:4/17/2014)... team led by researchers at UC Davis has shown ... key role in cell division, also boosts the mitochondrial ... time the complex has been shown to perform both ... excellent target to control cellular energy production, potentially advancing ... online today in the journal Developmental Cell . ...
Breaking Medicine News(10 mins):Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... a competitive application process, Michele D. Kipke, PhD, Vice ... Hospital Los Angeles, was awarded a $420,000 grant which ... Autism Treatment Network (ATN) as an ATN Center of ... Speaks, which is North America,s largest autism science and ...
... hemorrhagic fever in humans, has no known cure or vaccine. ... scientists has uncovered a family of small molecules which appear ... inhibit its entry into human cells. The results are ... and are now online. Previous studies have shown ...
... discovered that cells lining the blood vessels secrete molecules ... invading other tissues, a finding that could lead to ... professor in the MIT-Harvard Division of Health Sciences and ... a patient,s tumor could shrink a tumor or prevent ...
... to research conducted at the Oregon National Primate Research Center ... that oral contraceptives cause weight gain appears to be false. ... appear in next month,s edition of the journal Human ... reveal that contraceptives and the possibility that they may cause ...
... WEDNESDAY, Jan. 19 (HealthDay News) -- Many U.S. transplant ... trying to develop new safeguards that would protect and ... one-third of transplant surgeons in the nation "overreacted" to ... contracted HIV after receiving organs from a single donor ...
... a gene that is mutated in one in three patients ... of a frequently mutated gene will provide new insights into ... critical in the continued effort to improve treatment for renal ... to be mutated in 88 cases out of 257 clear ...
Cached Medicine News:Health News:Children's Hospital Los Angeles joins Autism Treatment Network 2Health News:Small molecules may prevent ebola infection 2Health News:MIT scientists discover cancer-fighting role for cells 2Health News:MIT scientists discover cancer-fighting role for cells 3Health News:MIT scientists discover cancer-fighting role for cells 4Health News:Do birth control pills cause weight gain? New research says no 2Health News:Research provides new kidney cancer clues 2Health News:Research provides new kidney cancer clues 3
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
Medicine Products: